AmYmed: Antibodies for amyloidosis typing - Reliable tools for accurate amyloid classification
Precise characterization of amyloid deposits is essential for understanding disease mechanisms, informing therapy decisions, and enhancing patient outcomes. AmyMed offers a unique range of well-characterized antibodies developed specifically for amyloidosis research and diagnostic applications.
The antibodies provide the precision required for amyloid classification and diagnostic workflows. By using well-characterized, reliable tools, you can improve the accuracy of amyloidosis typing and contribute to more effective patient management.
Antibody portfolio
Amyloidosis typing antibodies
Y110 – Anti-AA (mcC)
Y120 – Anti-Alλ (HAR)
Y130+1 – Anti-Alλ (ULI/LAT)
Y140+1 – Anti-Alκ (SIN)
Y150+1 – Anti-Alκ (KRA/KUN)
Y160+1 – Anti-AHγ (MIX)
Y170 – Anti-Aß2M (WOE)
Y180 – Anti-ATTR (TIE)
Y190 – Anti-FibAα
Y200 – Anti-ApoA1
Multiplex Kits
Y-kit – amY-Kit
Y-kit-red – amY-Kit Red
Key Features
Specificity: Developed and validated for amyloid deposits in human tissues.
Breadth: Coverage of the most clinically relevant amyloidogenic proteins.
Reproducibility: Consistent performance across applications.
Flexibility: Available as individual antibodies or in convenient panel kits.
Applications
- Histopathological diagnostics – Distinguishing amyloid subtypes in patient biopsies.
- Clinical research – Supporting translational studies on amyloidosis pathogenesis.
- Drug development – Enabling accurate preclinical and biomarker research.
